PPARG and osteosarcoma: In conclusion, our study revealed that four NR modulators, namely, the RARb antagonist LE135, PPARg antagonist T0070907, LXR agonist T0901317 and Rev-Erba agonist SR9011, effectively inhibit the growth of osteosarcoma in vitro and in vivo.